Loading organizations...
Key people at PSI CRO AG.
PSI CRO AG operates as a global full-service Contract Research Organization (CRO), providing comprehensive clinical development services. The company specializes in the management of Phase II and III clinical trials, offering expertise in various therapeutic areas, including oncology and hematology. PSI CRO focuses on delivering predictable patient enrollment and high-quality data to advance drug development programs efficiently for its clients.
The company was established in 1995, originating in Switzerland and growing into a prominent international player in the clinical research sector. PSI CRO maintains its position as a privately owned and independent entity, a characteristic that has shaped its operational philosophy over decades. This independence underpins its approach to client partnerships and project execution within the competitive CRO landscape.
PSI CRO serves biopharmaceutical sponsors seeking reliable and effective solutions for their complex clinical trials. The company's vision centers on optimizing clinical research processes, aiming to reduce development timelines and achieve successful study outcomes for novel treatments. Their long-term objective involves consistently delivering excellence in trial execution, supporting partners in bringing new therapies to patients.
PSI CRO AG is a privately owned, full-service global Contract Research Organization (CRO) headquartered in Zug, Switzerland, specializing in planning and executing Phase II and III pivotal registration clinical trials across multiple therapeutic areas.[1][2][3][6] With 3,000 full-time employees operating in 56 countries, PSI reported 15% revenue growth in 2024, on-time project delivery above 90%, and a global staff turnover rate of just 9%, serving pharmaceutical, biotechnology, medical companies, universities, and government institutions through services like clinical research, data management, project management, and laboratory support.[1][2][3] The company boasts a 90% repeat and referral business rate, emphasizing reliability in an industry plagued by delays and high turnover.[1][6]
Founded in 1995 in Switzerland, PSI CRO AG has grown organically for 30 years under its original, unchanging management team, remaining the only fully independent and privately owned CRO of its size.[1][6] From its inception, PSI targeted the clinical research industry's core challenge: poor patient enrollment, which affects 90% of trials.[1][6] Early focus on organic growth and stability enabled global expansion to 56 countries, with headquarters at Baarerstrasse 113a, Zug.[1][4][5] Pivotal moments include consistent on-time delivery and earning CRO Leadership Awards for six consecutive years in expertise, quality, and reliability, as voted by sponsors.[6][7]
PSI CRO rides the wave of accelerating biopharma innovation, particularly in complex therapeutics like cell & gene therapy, radiopharmaceuticals, and rare diseases, where timely Phase II/III trials are critical for regulatory approval and market entry.[5][7] Its timing aligns with post-pandemic demand for faster, predictable enrollment amid global supply chain strains and talent shortages in clinical research—issues PSI counters with organic growth and low turnover.[1] Market forces favoring PSI include rising outsourcing to CROs (as in-house pharma capabilities shrink) and AI-driven tools like VISIONAL™ that optimize feasibility amid regulatory pressures from FDA/EMA.[6][7] By enabling on-time trials, PSI influences the ecosystem, speeding therapies to patients and supporting smaller biotechs lacking internal expertise.[1][3]
In 2025—its 30th year—PSI's momentum positions it for continued double-digit growth, leveraging GenAI enhancements and global footprint to capture share in high-growth areas like oncology and gene therapies.[1][7] Trends like AI protocol optimization, radiopharma expansion, and decentralized trials will amplify its edge, potentially pushing employee count beyond 3,000 while maintaining sub-10% turnover.[1][7] As biopharma consolidates outsourcing, PSI's independence and reliability could elevate its influence, drawing more referrals and setting benchmarks for CRO stability in a volatile sector—proving that in clinical trials, trust truly delivers results.
Key people at PSI CRO AG.
